QLS-1128
- Generic Name
- QLS-1128
A Study to Compare QLS1128 With Placebo in Symptomatic Participants With Mild to Moderate COVID-19
- First Posted Date
- 2023-03-07
- Last Posted Date
- 2023-03-10
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 1220
- Registration Number
- NCT05758519
- Locations
- π¨π³
Qilu Pharmaceutical Co., Ltd., Jinan, Shandong, China
A Phase 2 Study to Evaluate the Efficacy and Safety of QLS1128 Orally in Symptomatic Participants With Mild to Moderate COVID-19
- First Posted Date
- 2023-01-19
- Last Posted Date
- 2023-01-19
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 360
- Registration Number
- NCT05689203
- Locations
- π¨π³
Qilu Pharmaceutical Co., Ltd., Jinan, Shandong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
Β© Copyright 2025. All Rights Reserved by MedPath